Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
IL-13 induces loss of CFTR in ionocytes and reduces airway epithelial fluid absorption
Guillermo S. Romano Ibarra, … , Ian M. Thornell, David A. Stoltz
Guillermo S. Romano Ibarra, … , Ian M. Thornell, David A. Stoltz
Published September 10, 2024
Citation Information: J Clin Invest. 2024;134(21):e181995. https://doi.org/10.1172/JCI181995.
View: Text | PDF
Research Article Pulmonology

IL-13 induces loss of CFTR in ionocytes and reduces airway epithelial fluid absorption

  • Text
  • PDF
Abstract

The airway surface liquid (ASL) plays a crucial role in lung defense mechanisms, and its composition and volume are regulated by the airway epithelium. The cystic fibrosis transmembrane conductance regulator (CFTR) is abundantly expressed in a rare airway epithelial cell type called an ionocyte. Recently, we demonstrated that ionocytes can increase liquid absorption through apical CFTR and basolateral barttin/chloride channels, while airway secretory cells mediate liquid secretion through apical CFTR channels and basolateral NKCC1 transporters. Th2-driven (IL-4/IL-13) airway diseases, such as asthma, cause goblet cell metaplasia, accompanied by increased mucus production and airway secretions. In this study, we investigate the effect of IL-13 on chloride and liquid transport performed by ionocytes. IL-13 treatment of human airway epithelia was associated with reduced epithelial liquid absorption rates and increased ASL volume. Additionally, IL-13 treatment reduced the abundance of CFTR-positive ionocytes and increased the abundance of CFTR-positive secretory cells. Increasing ionocyte abundance attenuated liquid secretion caused by IL-13. Finally, CFTR-positive ionocytes were less common in asthma and chronic obstructive pulmonary disease and were associated with airflow obstruction. Our findings suggest that loss of CFTR in ionocytes contributes to the liquid secretion observed in IL-13–mediated airway diseases.

Authors

Guillermo S. Romano Ibarra, Lei Lei, Wenjie Yu, Andrew L. Thurman, Nicholas D. Gansemer, David K. Meyerholz, Alejandro A. Pezzulo, Paul B. McCray, Ian M. Thornell, David A. Stoltz

×

Figure 1

IL-13 treatment increases airway epithelial goblet cell number and bumetanide-sensitive Isc.

Options: View larger image (or click on image) Download as PowerPoint
IL-13 treatment increases airway epithelial goblet cell number and bumet...
(A) MUC5AC immunostaining of human airway epithelial cells treated with vehicle control or IL-13 for 6 or 28 days. Scale bar: 100 μm. (B) Quantification of goblet cell abundance (MUC5AC-positive cells) by flow cytometry at various time points following vehicle control or IL-13 treatment. Data are from 8 independent donors. Each symbol represents an individual donor at a given time point. Not all donors are represented at each time point. (C) Representative short-circuit current (Isc) traces of human airway epithelial cultures exposed to vehicle control or IL-13. The following agents were added sequentially: apical amiloride, apical forskolin/IBMX, apical Ani9, apical CFTRinh-172, and basolateral bumetanide. n = 5 donor epithelia per treatment group. (D) Summary Isc values for donor epithelia treated with vehicle control or IL-13 for 3–4 weeks. Ctrl, control.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts